Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    5-APDI molecular structure

    5-APDI Stats & Data

    Iap 2-api 5-iap Indanametamine Indanylamphetamine
    NPS DataHub
    MW175.27
    FormulaC12H17N
    CAS13396-94-6
    IUPAC1-(2,3-dihydro-1H-inden-5-yl)propan-2-amine
    SMILESCC(N)Cc1ccc2CCCc2c1
    InChIKeyQYVNZHBQYJRLEX-UHFFFAOYSA-N
    Phenethylamines
    Chemical Class Substituted amphetamine
    Psychoactive Class Psychedelic / Stimulant

    Receptor Profile

    Receptor Actions

    Inhibitors
    Dopamine reuptake inhibitor
    Norepinephrine reuptake inhibitor
    Other
    Serotonin releasing agent (selective)

    Effect Profile

    Curated + 9 Reports
    Psychedelic 2.5

    Mild auditory effects with low visuals and body load

    Visual Intensity×3
    3
    Headspace Depth×3
    0
    Auditory Effects×1
    4
    Body Load / Somatic Effects×1
    3
    Empathogen 5.1

    Moderate stimulation with mild empathy, euphoria, and sensory enhancement

    Empathy / Social Openness×3
    5
    Euphoria / Mood Elevation×2
    5
    Stimulation×1
    6
    Sensory Enhancement×1
    5
    Stimulant 3.5

    Mild stimulation and euphoria with moderate anxiety/jitters

    Stimulation / Energy×3
    5
    Euphoria / Mood Lift×2
    5
    Focus / Productivity×2
    0
    Anxiety / Jitters×1
    7
    Based on reports from:

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans; community estimates suggest ~4–6 h with active metabolites possibly extending effects.
    Addiction Potential
    Low to moderate. Primarily psychological craving reported; physical dependence not described. Rapid tolerance limits compulsive redosing.

    Tolerance Decay

    Full tolerance 1d Half tolerance 7d Baseline ~21d

    Rapid acute tolerance is frequently reported with SRAs; spacing of several weeks is prudent by analogy to MDMA. Estimates are heuristic and based on anecdotal patterns rather than formal PK/PD studies.

    Cross-Tolerances

    MDMA
    MDA
    Other serotonergic empathogens

    Experience Report Analysis

    Erowid
    16 Reports
    9 Single-substance
    2003–2007 Date Range
    1 With Age Data
    9 Effects Detected

    Demographics

    Gender Distribution

    Too few reports for a chart: gender is known from 16 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

    • Male 14 of 16
    • Not Specified 1 of 16
    • Female 1 of 16

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 9 experience reports (9 single-substance Erowid)

    9 Reports
    9 Effects Detected
    6 Positive
    3 Adverse
    0 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

    Too few reports for bars: these effects come from 9 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    Positive Effects 6

    Euphoria 6 of 9 70%
    Stimulation 5 of 9 70%
    Empathy 4 of 9 70%
    Introspection 3 of 9 70%
    Focus Enhancement 3 of 9 70%
    Color Enhancement 3 of 9 70%

    Adverse Effects 3

    Anxiety 5 of 9 70%
    Confusion 4 of 9 70%
    Jaw Clenching 3 of 9 70%

    Dosage Distribution

    Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.

    Median: 45.0 mg IQR: 32.5–50.0 mg n=11

    Real-World Dose Distribution

    Erowid

    From 17 of 21 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

    Oral (n=16)

    Median: 32.5mg 25th: 17.5mg 75th: 46.25mg 90th: 50.0mg

    Common Combinations

    Most co-occurring substances, as a share of all 16 reports filed under 5-APDI

    Too few reports for bars: these combinations come from 16 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    • Alcohol 3 of 16
    • THC 3 of 16

    Form / Preparation

    Most common forms and preparations, as a share of the 14 reports that give one

    Too few reports for bars: these forms come from 14 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    • Powder / Crystals 9 of 14
    • Capsule 4 of 14

    Body-Weight Dosing

    Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.

    Median: 0.63 mg/kg IQR: 0.469–0.665 mg/kg n=11

    Redose Patterns

    Redosing behavior across 14 reports

    4 of 14 Redosed
    1.4 Avg Doses
    150m Median Interval

    Too few reports for a chart: redosing is known from 14 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

    • Single dose 10 of 14
    • Redosed 4 of 14

    Harm Reduction

    drugs.wiki

    Identity/mislabelling risk: “IAP/5‑IAP/5‑APDI” has been inconsistently named and sometimes mis-sold; historical misrepresentation (e.g., 5‑IAI fiasco) underscores the need for GC/MS drug checking over reagent kits alone. Purity and identity should be verified where possible. Slow onset and long tail make premature redosing risky; tolerance can build intra‑session, leading to greater side‑effects with little added benefit. As a serotonergic releaser, it carries serotonin syndrome risk—especially with MAOIs, SSRIs/SNRIs, tramadol/meperidine, linezolid, and other SRAs. Hyperthermia is possible in warm, crowded settings; take cooling breaks, avoid vigorous exertion, and maintain light, spaced fluids. Conversely, overhydration can cause hyponatraemia; sip small amounts regularly and consider electrolytes rather than rapid overconsumption of water. GI side‑effects (nausea, cramping, diarrhoea) are common with serotonergic drugs given the high proportion of peripheral 5‑HT in the gut. Cardiovascular strain (tachycardia, sweating) and bruxism are frequently reported; avoid combining with other stimulants. Insufflation increases local irritation; avoid repeated lines. Intravenous use is strongly discouraged due to unknown solubility/excipients and lack of clinical formulation. Space sessions widely (several weeks) to reduce tolerance and mood after‑effects, by analogy to MDMA‑like agents. Use a thermometer if active for long periods; if overheating or severe agitation/confusion/tremor/clonus occur, seek medical help; benzodiazepines and external cooling are standard first‑aid while awaiting care.

    ← Back to 5-APDI